

State of Oklahoma SoonerCare Gavreto® (Pralsetinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	
Pharmacy billing (NDC:) Start Date (or date of next dose):	
Dose: Regimen:		:
	Billing Provider Inform	nation
Pharmacy NPI:	Pharmacy Name:	
Pharmacy Phone:	Pharmacy Fax:	
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria		
For Initial Authorization 1. Please indicate the diagnosis and information: Non-Small Cell Lung Cancer (NSCLC) A. Is diagnosis recurrent, advanced,or metastatic NSCLC? YesNo B. Is tumor rearranged during transfection (RET) fusion positive? YesNo C. Will pralsetinib be used as a single agent? YesNo Thyroid Cancer A. Is disease advanced or metastatic? YesNo B. Is diagnosis RET-mutant medullary thyroid cancer requiring systemic therapy? YesNo C. Is diagnosis RET fusion-positive thyroid cancer? YesNo i. If yes, does member require systemic therapy? YesNo ii. Is radioactive iodine appropriate for this member? YesNo a. If appropriate, is member refractory to radioactive iodine? YesNo D. Will pralsetinib be used as a single agent? YesNo If diagnosis is not listed above, please indicate diagnosis: Additional Information: For Continued Authorization: 1. Date of last dose: 2. Does member have any evidence of progressive disease while on pralsetinib? Yes No 3. Has the member experienced adverse drug reactions related to pralsetinib therapy? Yes No If yes No PresNo Prescriber Signature: Date: I certify that the indicated treatment is medically necessary and all information is true and		
correct to the best of my k	nowledge.	ry and all information is true and finecessary. Failure to complete this form in full will

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 173 5/23/2023